Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268367 | 0.86 | ABCC8 (0.37) | ABCC8KCNJ11 | |
| SCHEMBL4410206 | 0.84 | ABCC8 (0.47) | ABCC8KCNJ11 | |
| SCHEMBL13949247 | 0.83 | ABCC8 (0.37) | ABCC8KCNJ11 | |
| SCHEMBL4410466 | 0.81 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| Tifenazoxide SCHEMBL2109690 | 0.81 | ABCC8 (0.45) | ABCC8KCNJ11 | |
| SCHEMBL4563273 | 0.81 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL6802837 | 0.80 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL7078790 | 0.79 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL7077604 | 0.78 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL2344068 | 0.77 | ABCC8 (0.45) | ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| EP-1338600-A1 | Fused 1,2,4-Thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2003-08-27 | — | — | EP | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| EP-1140945-B1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-06-04 | — | — | EP | claimed |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | HANSEN JOHN BONDO (DK) | 2002-07-04 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| US-6329367-B1 | NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS | NOVO NORDISK A/S (DK) | 2001-12-11 | — | — | US | claimed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1140945-B1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-06-04 | — | — | EP | disclosed |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | HANSEN JOHN BONDO (DK) | 2002-07-04 | — | — | US | disclosed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| US-6329367-B1 | NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS | NOVO NORDISK A/S (DK) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC8 415/4885KCNJ11 18/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC8 605/4885KCNJ11 24/4885 |
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | ABCC8 73/4885KCNJ11 1/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | ABCC8 63/4885KCNJ11 1/4885 |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | CYP4F3, TBXAS1, NR3C2 | ABCC8 3610/4885KCNJ11 801/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | ABCC8 944/4885KCNJ11 7/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | ABCC8 3372/4885KCNJ11 1274/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | ABCC8 985/4885KCNJ11 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.